Our CDMO partner, Bachem, presented Jitsubo’s proprietary Molecular Hiving™ Technology—a Tag-assisted Liquid Phase Peptide Synthesis Technology, at the TIDES USA 2025 conference.

Learn more: https://www.bachem.com/webinar/peptides-nce/peptide-synthesis-by-molecular-hiving/

Jitsubo CO., LTD. announced  the signing of an exclusive manufacturing license agreement with Novo Nordisk A/S（2880 Bagsvaerd, Denmark, hereinafter “Novo Nordisk”）for Novo Nordisk to use and have manufacturing rights to Jitsubo’s proprietary peptide manufacturing technology, Molecular Hiving^TM, for synthesis of peptides in the field of obesity, diabetes, and the related therapeutic areas.

News Release PDF